Stock ORMP ORAMED PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Oramed Pharmaceuticals Inc.

Equities

ORMP

US68403P2039

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.3 USD -2.95% Intraday chart for Oramed Pharmaceuticals Inc. +4.55% -0.43%
Mar. 19 Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024 CI
Mar. 06 Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Oramed Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

fd6efb903629.6wfodBCVg5hYE4foAOVjhwTpq03zEphFRxp1GzJXdIg.3z6KFkfR6ek6WM3YdLBQ622vhiTGZ_MjMn0fNkovM-2KYNA7QKG36iB89A~e8389626e7700c7e84a721266dda6caa

Analyst Recommendations on Oramed Pharmaceuticals Inc.

Canaccord Genuity Adjusts Price Target on Oramed Pharmaceuticals to $2 From $3, Maintains Hold Rating MT
HC Wainwright Downgrades Oramed Pharmaceuticals to Neutral From Buy MT
Cantor Fitzgerald Downgrades Oramed Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $5 From $20 MT
Canaccord Genuity Downgrades Oramed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $3 From $30 MT
Aegis Capital Adjusts Price Target for Oramed Pharmaceuticals to $30 From $35, Maintains Buy Rating MT
Cantor Fitzgerald Starts Oramed Pharmaceuticals at Overweight With $20 Price Target MT
HC Wainwright Adjusts Price Target on Oramed Pharmaceuticals to $32 From $17, Maintains Buy Rating MT
ORAMED PHARMACEUTICALS : Canaccord Genuity Starts Oramed Pharmaceuticals at Buy With $27 Price Target MT
ORAMED PHARMACEUTICALS : National Securities Starts Oramed Pharmaceuticals at Buy with $23 Price Target MT
ORAMED PHARMACEUTICALS : Aegis Capital Adjusts Price Target on Oramed Pharmaceuticals to $12 From $6, Maintains Buy Rating MT
ORAMED PHARMACEUTICALS : Alliance Global Starts Oramed Pharmaceuticals at Buy With $11 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.3 USD
Average target price
4.25 USD
Spread / Average Target
+84.78%
High Price Target
4.25 USD
Spread / Highest target
+84.78%
Low Price Target
4.25 USD
Spread / Lowest Target
+84.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Oramed Pharmaceuticals Inc.

Canaccord Genuity
HC Wainwright
Cantor Fitzgerald
Aegis Capital
National Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ORMP Stock
  4. Consensus Oramed Pharmaceuticals Inc.